Alnylam Pharmaceuticals (ALNY) shares rallied 6% in the last trading session to close at $482.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.6% gain over the past four weeks.The recent stock price gain can be attributed to the positive investor mindset regarding the continued strong uptake of Alnylam’s lead marketed drug Amvuttra, which was initially approved for polyneuropathy of hATTR amyloidosis. In ...